Natalizumab (Tysabri)

References

1. 1.↵
   1. Rudick RA,
   2. Stuart WH,
   3. Calabresi PA,
   4. et al

   . Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006; 354: 911– 23

   CrossRefPubMedWeb of Science
2. 2.↵
   1. Polman CH,
   2. O'Connor PW,
   3. Havrdova,
   4. et al

   . A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354: 899– 910

   CrossRefPubMedWeb of Science
3. 3.↵
   1. Gordon FH,
   2. Lai CW,
   3. Hamilton MI,
   4. et al

   . A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn's disease. Gastroenterology 2001; 121: 268– 74

   CrossRefPubMed
4. 4.↵
   1. Ghosh S,
   2. Goldin E,
   3. Gordon FH,
   4. et al

   . Natalizumab for active Crohn's disease. N Engl J Med 2003; 348: 24– 32

   CrossRefPubMedWeb of Science
5. 5.↵
   1. Sandborn WJ,
   2. Colombel JF,
   3. Enns R,
   4. et al

   . Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 2005; 353: 1912– 25

   CrossRefPubMedWeb of Science
6. 6.↵
   Department of Health and Human Services. Tysabri risk minimization action plan: summary of TOUCH. http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM107197.pdf. Accessed June 28, 2010
7. 7.↵
   1. Lobb RR,
   2. Hemler ME

   . The pathophysiologic role of alpha 4 integrins in vivo. J Clin Invest 1994; 94: 1722– 28

   PubMedWeb of Science
8. 8.↵
   1. Yednock TA,
   2. Cannon C,
   3. Fritz LC,
   4. et al

   . Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature 1992; 356: 63– 66

   CrossRefPubMed
9. 9.↵
   1. Brocke S,
   2. Piercy C,
   3. Steinman L,
   4. et al

   . Antibodies to CD44 and integrin alpha4, but not L-selectin, prevent central nervous system inflammation and experimental encephalomyelitis by blocking secondary leukocyte recruitment. Proc Natl Acad Sci U S A 1999; 96: 6896– 901

   Abstract/FREE Full Text
10. 10.↵
    1. Rice GP,
    2. Hartung HP,
    3. Calabresi PA

    . Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale. Neurology 2005; 64: 1336– 42

    Abstract/FREE Full Text
11. 11.↵
    1. Ley K,
    2. Laudanna C,
    3. Cybulsky MI,
    4. et al

    . Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat Rev Immunol 2007; 7: 678– 89

    CrossRefPubMedWeb of Science
12. 12.↵
    1. Goodin DS,
    2. Cohen BA,
    3. O'Connor P,
    4. et al

    . Assessment: the use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008; 71: 766– 73

    Abstract/FREE Full Text
13. 13.↵
    1. Rudick RA,
    2. Sandrock A

    . Natalizumab: alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS. Expert Rev Neurother 2004; 4: 571– 80

    CrossRefPubMed
14. 14.↵
    1. Miller DH,
    2. Khan OA,
    3. Sheremata WA,
    4. et al

    . A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2003; 348: 15– 23

    CrossRefPubMedWeb of Science
15. 15.↵
    1. Clifford DB,
    2. DeLuca A,
    3. Simpson DM,
    4. et al

    . Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol 2010; 9: 438– 46

    CrossRefPubMedWeb of Science
16. 16.↵
    1. Bezabeh S,
    2. Flowers CM,
    3. Kortepeter C,
    4. et al

    . Review article: clinically significant liver injury in patients treated with natalizumab (TYSABRI). Aliment Pharmacol Ther 2010; 31: 1028– 35. Epub 2010 Feb 16

    PubMed
17. 17.↵
    Center for Drug Evaluation and Research (CDER). Tysabri (Natalizumab) biologic license application 125104/15. In: Proceedings of the Peripheral and Central Nervous System Drugs Advisory Committee, Gaithersburg, Maryland. 3 7–8, 2006; available at http://www.fda.gov/ohrms/dockets/ac/06/slides/2006-4208S1-Slide-Index.htm. Accessed June 28, 2010
18. 18.↵
    1. Ismail A,
    2. Kemp J,
    3. Sharrack B

    . Melanoma complicating treatment with natalizumab (Tysabri) for multiple sclerosis. J Neurol 2009; 256: 1771– 72. Epub 2009 Jul 16

    CrossRefPubMedWeb of Science
19. 19.↵
    1. Mullen JT,
    2. Vartanian TK,
    3. Atkins MB

    . Melanoma complicating treatment with natalizumab for multiple sclerosis. N Engl J Med 2008; 358: 647– 48

    CrossRefPubMedWeb of Science